This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.
Melissa Eisen, MD
Advertisement
Articles by Melissa Eisen, MD
Advertisement
Latest Updated Articles
- Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia
Published: July 11th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Balancing Efficacy and Safety in BTKi Therapy
3
Measles Outbreaks Cause Financial, Public Health Burden in US
4
Empagliflozin Reduces HF Risk After AMI in Patients With or Without Diabetes, CKD
5
